Vaccine against uterine cancer soon on market of Serbia?

Source: Tanjug Thursday, 01.01.1970. 11:50
Comments
Podeli

Company "Merck Sharp & Dohme" (MSD), which has been present on the local market since 1996, works on the obtaining of the approval for sale of revolutionary vaccine against uterine cancer named "Silgard" in Serbia.

Let us remind that the Advisory Board for Immunization of the American CEnter for Control and Prevention of Diseases unanimously backed the recommendation that the girls and women, aged between 11 and 26, should be vaccinated with the MSD vaccine, which is called "gardasil" in USA. Company "Merck" tested "gardasil" on 27,000 women in 33 countries and the results of the clinical testing showed that the vaccine was 100% efficient aggainst the viruses that are responsilbe for 70% of infections caused by human papilloma virus.

By the way, the uterine cancer is the second most often type of that women's disease. Every year, half million new cases are registered.

Comments
Your comment
Full information is available only to commercial users-subscribers and it is necessary to log in.

Forgot your password? Click here HERE

For free test use, click HERE

Follow the news, tenders, grants, legal regulations and reports on our portal.
Registracija na eKapiji vam omogućava pristup potpunim informacijama i dnevnom biltenu
Naš dnevni ekonomski bilten će stizati na vašu mejl adresu krajem svakog radnog dana. Bilteni su personalizovani prema interesovanjima svakog korisnika zasebno, uz konsultacije sa našim ekspertima.